$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224018935 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$150.6K	$645.8K
YoY Change		57.39%	176.6%
Cost Of Revenue		$48.23K	$188.1K
YoY Change		73.55%	246.3%
Gross Profit		$102.3K	$457.7K
YoY Change		50.77%	155.46%
Gross Profit Margin		67.97%	70.87%
Selling, General & Admin	$1.156M	$7.545M	$17.06M
YoY Change	-70.18%	471.48%	104.77%
% of Gross Profit		7373.65%	3727.99%
Research & Development	$312.3K	$387.1K	$2.177M
YoY Change	-54.83%	-43.14%	-45.29%
% of Gross Profit		378.31%	475.58%
Depreciation & Amortization	$121.3K	$210.3K	$841.2K
YoY Change	-42.33%	-0.03%	-0.03%
% of Gross Profit		205.51%	183.79%
Operating Expenses	$1.589M	$8.150M	$34.54M
YoY Change	-67.82%	268.54%	-7.89%
Operating Profit	-$1.589M	-$8.048M	-$34.09M
YoY Change	-66.92%	275.44%	-8.67%
Interest Expense	-$3.438M	-$7.697M	-$30.22M
YoY Change	-74.39%	569.92%	983.59%
% of Operating Profit
Other Income/Expense, Net	-$2.483M	$18.70M	-$31.26M
YoY Change	-84.26%	400.09%	3612.31%
Pretax Income	-$4.073M	-$9.766M	-$65.35M
YoY Change	-80.21%	-58.56%	71.22%
Income Tax
% Of Pretax Income
Net Earnings	-$4.073M	-$9.766M	-$65.35M
YoY Change	-80.21%	-58.56%	71.22%
Net Earnings / Revenue		-6486.22%	-10118.6%
Basic Earnings Per Share	-$0.03		-$1.44
Diluted Earnings Per Share	-$0.03	-$0.19	-$1.44
COMMON SHARES
Basic Shares Outstanding	131.8M shares	46.67M shares	45.47M shares
Diluted Shares Outstanding	131.8M shares		45.47M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.220K	$148.5K	$148.5K
YoY Change	-97.46%	-70.94%	-70.94%
Cash & Equivalents	$5.222K	$148.5K
Short-Term Investments
Other Short-Term Assets	$854.2K	$699.4K	$699.4K
YoY Change	40.87%	-37.87%	-37.87%
Inventory	$26.87K	$24.86K	$24.86K
Prepaid Expenses	$854.1K	$699.4K
Receivables		$60.28K	$60.28K
Other Receivables	$35.85K	$35.80K	$35.80K
Total Short-Term Assets	$922.1K	$968.8K	$968.8K
YoY Change	-12.89%	-50.45%	-50.45%
LONG-TERM ASSETS
Property, Plant & Equipment		$12.50K	$1.114M
YoY Change		-0.36%	-25.63%
Goodwill	$5.416M	$5.416M
YoY Change	-24.68%	-24.68%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.5K	$152.5K	$152.5K
YoY Change	-11.91%	-58.69%	-58.69%
Total Long-Term Assets	$20.61M	$21.05M	$21.05M
YoY Change	-42.62%	-42.7%	-42.7%
TOTAL ASSETS
Total Short-Term Assets	$922.1K	$968.8K	$968.8K
Total Long-Term Assets	$20.61M	$21.05M	$21.05M
Total Assets	$21.53M	$22.02M	$22.02M
YoY Change	-41.77%	-43.1%	-43.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.269M	$2.322M	$2.216M
YoY Change	60.41%	70.06%	81.0%
Accrued Expenses	$439.5K	$434.1K	$539.8K
YoY Change	2.5%	2.5%	-4.37%
Deferred Revenue
YoY Change
Short-Term Debt	$990.6K	$2.694M	$2.694M
YoY Change
Long-Term Debt Due	$18.56M	$14.92M	$14.92M
YoY Change	45.6%	1217.23%	1217.23%
Total Short-Term Liabilities	$23.55M	$20.60M	$20.60M
YoY Change	13.11%	605.14%	605.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$7.363M	$6.073M	$6.073M
YoY Change	-14.21%	-61.05%	-61.05%
Total Long-Term Liabilities	$7.363M	$6.073M	$6.073M
YoY Change	-17.18%	-66.89%	-66.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.55M	$20.60M	$20.60M
Total Long-Term Liabilities	$7.363M	$6.073M	$6.073M
Total Liabilities	$30.91M	$26.68M	$26.68M
YoY Change	4.05%	25.44%	25.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.6M	-$151.3M
YoY Change	48.13%	75.99%
Common Stock	$131.8K	$131.8K
YoY Change	190.51%	225.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.380M	-$4.661M	-$4.661M
YoY Change
Total Liabilities & Shareholders Equity	$21.53M	$22.02M	$22.02M
YoY Change	-41.77%	-43.1%	-43.1%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.073M	-$9.766M	-$65.35M
YoY Change	-80.21%	-58.56%	71.22%
Depreciation, Depletion And Amortization	$121.3K	$210.3K	$841.2K
YoY Change	-42.33%	-0.03%	-0.03%
Cash From Operating Activities	-$732.9K	-$1.214M	-$4.685M
YoY Change	-38.81%	-23.46%	-56.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	732.0K	887.5K	$4.322M
YoY Change	-31.8%	-2.98%	-40.71%
NET CHANGE
Cash From Operating Activities	-732.9K	-1.214M	-$4.685M
Cash From Investing Activities
Cash From Financing Activities	732.0K	887.5K	$4.322M
Net Change In Cash	-930.0	-326.5K	-$362.4K
YoY Change	-99.25%	-51.37%	-89.82%
FREE CASH FLOW
Cash From Operating Activities	-$732.9K	-$1.214M	-$4.685M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001413754
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent		usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
CY2022	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement		usd
CY2022	MRZM	Shares Issued For Services SharesIssuedForServices		usd
CY2022	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement		usd
CY2023	us-gaap	Other Operating Income OtherOperatingIncome		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment		usd
CY2022	MRZM	Shares Issued On Debt Conversion SharesIssuedOnDebtConversion		usd
CY2023	MRZM	Warrants Repurchased And Retired WarrantsRepurchasedAndRetired		usd
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2023	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
CY2022	MRZM	Debt Accretion Expenses DebtAccretionExpenses		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q4	us-gaap	Share Price SharePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	MRZM	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate		pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	MRZM	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-53223
CY2023	dei	Entity Registrant Name EntityRegistrantName	MARIZYME, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5464863
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	555 Heritage Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33458
CY2023	dei	City Area Code CityAreaCode	(561)
CY2023	dei	Local Phone Number LocalPhoneNumber	935-9955
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3310195	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	131793088	shares
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash Cash	148465	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	60284	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87801	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	35797	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15310	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	699377	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1125761	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	24855	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	215566	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	968778	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1955303	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12545	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1101211	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14364129	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	122457	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	339091	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5416000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	21046297	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	36732335	usd
CY2023Q4	us-gaap	Assets Assets	22015075	usd
CY2022Q4	us-gaap	Assets Assets	38687638	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2322064	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1365443	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	633692	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1132829	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	14288335	usd
CY2023Q4	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent	2694256	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434082	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20602582	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2921767	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667129	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	2751633	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4823725	usd
CY2023Q4	MRZM	Contingent Liabilities ContingentLiabilities	5406000	usd
CY2022Q4	MRZM	Contingent Liabilities ContingentLiabilities	9707000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6073129	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18343886	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26675711	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21265653	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	131792	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131793088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131793088	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40528	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	146543921	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370890	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151336349	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4660636	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22015075	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38687638	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	645810	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	233485	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	188108	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	54319	usd
CY2023	us-gaap	Gross Profit GrossProfit	457702	usd
CY2022	us-gaap	Gross Profit GrossProfit	179166	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	2300384	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	2082079	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	1317581	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2176740	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3978826	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	526597	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1905948	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	841217	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	841444	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	218794	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14244375	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24350000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	12918530	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1922696	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	34544218	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	37502962	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-34086516	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-37323796	usd
CY2023	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	30224223	usd
CY2022	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	2789255	usd
CY2023	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	4301000	usd
CY2022	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1606000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	795934	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	755364	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	338181	usd
CY2023	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-6888475	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31260400	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-842074	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-65346916	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38165870	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.44
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45473190	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45473190	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40727092	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40727092	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1905948	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6191575	usd
CY2022	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3000	usd
CY2022	MRZM	Adjustments To Additional Paid In Capital Warrants Repurchased And Retired AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchasedAndRetired	200000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38165870	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9340773	usd
CY2023	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Debt Extinguishment AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnDebtExtinguishment	19058426	usd
CY2023	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Promissory Note AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnPromissoryNote	1333128	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9083295	usd
CY2023	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	265216	usd
CY2023	MRZM	Stock Issued During Period Warrants Cancelled In Debt Extinguishment StockIssuedDuringPeriodWarrantsCancelledInDebtExtinguishment	-8426927	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	11496701	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-65346916	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4660636	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-65346916	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38165870	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	841217	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	841444	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	526597	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1905948	usd
CY2023	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	30224223	usd
CY2022	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	2789255	usd
CY2023	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-9083295	usd
CY2022	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-1850533	usd
CY2023	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	4301000	usd
CY2022	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1606000	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-795934	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	755364	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	338181	usd
CY2023	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-6888475	usd
CY2023	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement	153600	usd
CY2023	MRZM	Shares Issued For Services SharesIssuedForServices	168000	usd
CY2023	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement	1333128	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14244375	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24350000	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	3000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-7030	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	53154	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-426384	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	868592	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-190711	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	193213	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2197191	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-228684	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	230153	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1132634	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4684835	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10852148	usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2840000	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	6500743	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	265216	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1381469	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	954767	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	164250	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	167836	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4322435	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7290674	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-362400	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3561474	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4072339	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148465	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2023	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	27528235	usd
CY2022	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	2338379	usd
CY2023	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	19403385	usd
CY2022	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	4341042	usd
CY2023	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	2264133	usd
CY2022	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	278678	usd
CY2023	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment	8426927	usd
CY2023	MRZM	Shares Issued On Debt Conversion SharesIssuedOnDebtConversion	9424914	usd
CY2022	MRZM	Warrants Repurchased And Retired WarrantsRepurchasedAndRetired	200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151336349	usd
CY2023Q4	MRZM	Working Capital WorkingCapital	19633804	usd
CY2023Q4	us-gaap	Cash Cash	148465	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434082	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667129	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1101211	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1485023	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z4VMcUnZUbJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zvRMTTOkcYI6">Use of Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in accordance with GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities, and deferred tax valuations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2044000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3358000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5402000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zEZXyZFHpY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlzuSpby1WZk">Concentrations of Credit Risk</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zuhGTDkC0BD8" title="Cash federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14364129	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	five-and-a-half-year lease agreement
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053	sqft
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y6M29D
CY2023	us-gaap	Payments For Rent PaymentsForRent	356309	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	370945	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1101211	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	434082	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	444934	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	266034	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1145050	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	43839	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1101211	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29142745	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2308896	usd
CY2023Q4	MRZM	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-12469720	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14364129	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1467725	usd
CY2022Q4	MRZM	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-24350000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1774656	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5416000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	52866192	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	24350000	usd
CY2022	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	841172	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	12469720	usd
CY2023	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	841171	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	2216386	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	1224542	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	697	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	105678	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	140204	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2322064	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1365443	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4260594	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6692765	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4180071	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6500743	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	684682	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	338181	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19403385	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	9340774	usd
CY2023	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	19691390	usd
CY2022	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	2763749	usd
CY2023Q2	MRZM	Accrued Interest Payable Price Per Share AccruedInterestPayablePricePerShare	0.10
CY2023	MRZM	Debt Accretion Expenses DebtAccretionExpenses	2694256	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131793088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131793088	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2022Q1	MRZM	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	300000	shares
CY2022Q4	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	300000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0298	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1758	pure
CY2022Q4	us-gaap	Share Price SharePrice	2.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	MRZM	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y11M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62502	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62498	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3685943	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.29
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10M6D
CY2023	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	0	usd
CY2022	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	295750	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000000	usd
CY2023	MRZM	Share Based Compensation Arrangements By Share Based Payment Award Non Options Derivative Liabilities Extinguished ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsDerivativeLiabilitiesExtinguished	0.10
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	526597	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1905948	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	280347	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	172800	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	46255000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40733000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13722852	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8014646	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-162869	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-125758	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1658268	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	11711809	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	702460	usd
CY2023	MRZM	Income Tax Reconciliation Change In Deferred Trueups IncomeTaxReconciliationChangeInDeferredTrueups	2568076	usd
CY2022	MRZM	Income Tax Reconciliation Change In Deferred Trueups IncomeTaxReconciliationChangeInDeferredTrueups	-40912	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-15548	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-121202	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4883294	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9050744	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.179	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.018	pure
CY2023	MRZM	Effective Income Tax Rate Reconciliation Change In Deferred Deferred Trueup Tax EffectiveIncomeTaxRateReconciliationChangeInDeferredDeferredTrueupTax	0.039	pure
CY2022	MRZM	Effective Income Tax Rate Reconciliation Change In Deferred Deferred Trueup Tax EffectiveIncomeTaxRateReconciliationChangeInDeferredDeferredTrueupTax	-0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.003	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.075	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.237	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11735683	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9551121	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	255178	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	376380	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6212227	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3618128	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1082349	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	974819	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19285437	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14520448	usd
CY2023Q4	MRZM	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	255178	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2897	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	376380	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	285075	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	376380	usd
CY2023Q4	MRZM	Gross Deferred Tax Assets GrossDeferredTaxAssets	19027362	usd
CY2022Q4	MRZM	Gross Deferred Tax Assets GrossDeferredTaxAssets	14144068	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19027362	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14144068	usd
CY2023Q4	MRZM	Remaining Deferred Tax Assets Valuation Allowance RemainingDeferredTaxAssetsValuationAllowance	19027363	usd
CY2022Q4	MRZM	Remaining Deferred Tax Assets Valuation Allowance RemainingDeferredTaxAssetsValuationAllowance	14144068	usd

Files In Submission

Name	View Source	Status
0001493152-24-018935-index-headers.html	Edgar Link	pending
0001493152-24-018935-index.html	Edgar Link	pending
0001493152-24-018935.txt	Edgar Link	pending
0001493152-24-018935-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-21.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
mrzm-20231231_cal.xml	Edgar Link	unprocessable
mrzm-20231231_def.xml	Edgar Link	unprocessable
mrzm-20231231_lab.xml	Edgar Link	unprocessable
mrzm-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2024 Q2 Form 10-K Financial Statement

#000149315224018935 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2024 Q2 Form 10-K Financial Statement

#000149315224018935 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm